Facial Volume
Conditions
Keywords
restoration and/or augmentation of facial volume
Brief summary
The process of facial aging is a result of intricate alterations occurring at both the microscopic and macroscopic levels, leading to changes in facial volume. The observed alterations can be attributed to the process of bone structure resorption, the influence of gravity, redistribution of subcutaneous fat, and injury to the skin. Dermal fillers are utilized for the purpose of enhancing facial features in accordance with the aesthetic ideals of beauty. KOS® XL in the dermis regulates water balance, osmotic pressure and ion flow and functions as a sieve, excluding certain molecules, enhancing the extracellular domain of cell surfaces and stabilizes skin structures by electrostatic interactions. The Research Question of the present study is the following: to collect sufficient clinical data to demonstrate compliance with the General Safety and Performance Requirements of KOS® XL when used as intended.
Interventions
DEVICEKOS® XL
Delivery of medical device as injection
Sponsors
Opera CRO, a TIGERMED Group Company
Quantum Beauty Kozmetik
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Females and males ≥ 22years of age * Signed informed consent by the subject * Subject with grade from 3 to 5 on the FVLS. * Ability to follow study instructions and likely to complete all required visits * Reliable methods of contraception which result in a low failure rate (i.e. less than 1 % per year) for women of childbearing potential, e.g. implants, injectables, combined oral contraceptives, some intrauterine -devices, sexual abstinence or vasectomized partner) for the entire study duration.
Exclusion criteria
1. Using any new over-the-counter or prescription oral or topical, anti-wrinkle products within 30 days before enrolment or planning to begin using such products during the study (Subjects who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study). 2. Subject with a scar, moles or anything on the face which might interfere with the evaluation 3. Subject having received treatment with a laser, a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to inclusion 4. Subject having received injection with a resorbable filling product in the face area within the past 18 months prior to inclusion 5. Subject having received at any time injection with a slowly resorbable filling product (polylactic acid, calcium hydroxyapatite, combinations of hyaluronic acid (HA) and hypromellose, HA and dextran microbeads or HA and TriCalcium Phosphate (TCP), …) or with a non-resorbable filling product (polyacrylamide, silicone, combination of methacrylic polymers and collagen, polymer particles, …) 6. History of or active autoimmune disease/immune deficiency 7. Suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma…) 8. Prone to hypertrophic scars 9. History of allergy to hyaluronic acid or any of the product's components 10. History of allergy to lidocaine or local anaesthesia of amide compounds 11. Known case of porphyria 12. Pregnancy or lactation 13. Taking medications and/or substances known to increase coagulation time (e.g., aspirin, ibuprofen, or herbal supplements) 10 days prior to treatment 14. Have a condition or be in a situation that, in the physician's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study 15. Untreated epilepsy 16. Hypersensitivity to gram positive bacterial proteins as hyaluronic acid is produced by Streptococcus type bacteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in facial volume | 6 months | Mean change in facial volume from baseline on the Facial Volume Loss Scale (FVLS) at month 6 after the last treatment FVLS scale from 1 to 5; where 5 is representing severe indentation of one or more facial regions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Facial Volume Loss Scale (FVLS) | 1, 3 and 12 months | Change in the FVLS from baseline at 1, 3 and 12 months after the last treatment. FVLS scale from 1 to 5; where 5 is representing severe indentation of one or more facial regions |
| Proportion of participants with at least 1-point improvement on the Facial Volume Loss Scale (FVLS) | 1, 3, 6 and 12 months | Proportion of participants with at least 1-point improvement from baseline on the FVLS at 1, 3, 6 and 12 months after the last treatment (response rates). FVLS scale from 1 to 5; where 5 is representing severe indentation of one or more facial regions |
| Proportion of participants having a positive aesthetic evolution on the 5-point GAIS | 1, 3, 6 and 12 months | Proportion of participants having a positive aesthetic evolution on the 5-point Global Aesthetic Improvement Scale (GAIS) evaluated by the physician and subject at 1, 3, 6 and 12 months after the last treatment GAIS scale: from 1 (very much improved) to 5 (worse) |
| Change from baseline in FACE-Q satisfaction | 1, 3, 6 and 12 months | Change from baseline in FACE-Q satisfaction with cheekbones and FACE-Q satisfaction with chin at 1, 3, 6 and 12 months after the last treatment FACE-Q satisfaction with cheekbones scale: from 1 (very dissatisfied) to 4 (very satisfied) FACE-Q satisfaction with chin scale: from 1 (very dissatisfied) to 4 (very satisfied) |
| Short- and long-term adverse effects | 6 and 12 months | Short- and long-term adverse effects within 2 weeks of the initial or touch-up treatment and during 6, 12 months after the last treatment of the study course, respectively. |
Countries
Romania
Outcome results
None listed